Olmesartan/Amlodipine compared to Valsartan/Amlodipine reduce more LVH and Arterial Stiffness in Hypertensive patients
Journal of Hypertension:
Most patients with hypertension require more than one drug to attain recommended blood pressure (BP) targets. Initiating therapy with two agents is recommended for patients at high risk of a cardiovascular event.
Fixed drug combinations are increasingly used in antihypertensive therapy, so it is necessary to find the best combinations to achieve the best therapeutic effects not only in the control of arterial blood pressure (BP), but in other relevant aspects such as arterial stiffness (AS) of these patients (P).
Take Home Message:
Combination therapy is effective when comprised of agents with complementary mechanisms of action, such as calcium channel blockers (CCBs) and angiotensin II-receptor blockers (ARBs).
To evaluate the efficacy in reducing left ventricular hypertrophy (LVH) and arterial stiffness between two fixed combinations of antihypertensive drugs: olmesartan plus amlodipine (olm + aml) and valsartan plus amlodipine (val + aml) in patients with mild to moderate hypertension.
This study data suggest that the combination of OLM + AML is significantly higher than VAL + AML in reducing LVH and in reducing arterial stiffness indices indicating that not only provide a benefit in the control of blood pressure but also in the significant reduction in cardiovascular risk and mortality.
Doctors Liked to Read More
Objective:
Fixed drug combinations are increasingly used in antihypertensive therapy, so it is necessary to find the best combinations to achieve the best therapeutic effects not only in the control of arterial blood pressure (BP), but in other relevant aspects such as arterial stiffness (AS) of these patients (P).
To evaluate the efficacy in reducing left ventricular hypertrophy (LVH) and arterial stiffness between two fixed combinations of antihypertensive drugs: olmesartan plus amlodipine (olm + aml) and valsartan plus amlodipine (val + aml) in patients with mild to moderate hypertension.
Design and method:
Authors studied 126 P (53 ± 9 years) with mild-moderate hypertension with LVH who received two fixed combinations of antihypertensive drugs to maintain BP below 140/90 Hgmm in the office: olm + aml group: 66 P and val + aml group: 60 P to whom an echocardiographic study to detect LVH was performed by measuring the walls of the left ventricle and central systolic and diastolic pressures (CSBP, CDBP) were measured, the augmentation index (AI) and pulse wave velocity (PWV) at baseline and 32 weeks of treatment.
Results:
Data from both groups were compared and are shown in the following table:
Conclusions:
This study data suggest that the combination of OLM + AML is significantly higher than VAL + AML in reducing LVH and in reducing arterial stiffness indices indicating that not only provide a benefit in the control of blood pressure but also in the significant reduction in cardiovascular risk and mortality, being the HVI an independent marker of mortality in hypertensive patients, which should influence the selection of a fixed combination antihypertensive comprehensive control of our patients.
Comments
You must login to write comment